- Daratumumab in the multiple myeloma treatment in the light of the last clinical trials2017 | Faculty of Medicine in Hradec Králové
- Monoterapie daratumumabem u pentarefrakterního pacienta s mnohočetným myelomem2017 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 54767414MMY3004Publication without faculty affiliation
- Limited efficacy of daratumumab in multiple myeloma with extramedullary disease2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaPublication without faculty affiliation
- Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma2023 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 54767414MMY3007Publication without faculty affiliation
- A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab2021 | First Faculty of Medicine
- Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma2020 | First Faculty of Medicine, Second Faculty of Medicine
- Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population2019 | Publication without faculty affiliation
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial2023 | First Faculty of Medicine
- Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study2021 | Publication without faculty affiliation
- Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma2022 | First Faculty of Medicine
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR2018 | First Faculty of Medicine
- Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab2020 | First Faculty of Medicine
- Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial2021 | First Faculty of Medicine
- Můžeme myelom zcela vyléčit? Daratumumab, elotuzumab a isatuximab v léčbě mnohočetného myelomu2023 | First Faculty of Medicine
- Komentář ke studii (Daratumumab v monoterapii pacientů s relabujícím či refrakterním mnohočetným myelomem - poolovaná analýza)2017 | First Faculty of Medicine
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk2020 | First Faculty of Medicine
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial2020 | First Faculty of Medicine
- CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics2022 | Second Faculty of Medicine
- Novinky v léčbě mnohočetného myelomu v roce 20172018 | First Faculty of Medicine
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study2019 | First Faculty of Medicine
- Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study2020 | Faculty of Medicine in Hradec Králové
- Mnohočetný myelom2016 | First Faculty of Medicine
- ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma - final results of a phase I/IIa study2023 | Faculty of Medicine in Hradec Králové
- Biologická léčba u systémových amyloidóz2023 | First Faculty of Medicine